
Exenatide extended-release (Bydureon) approved as an add-on therapy to basal insulin in adults with type 2 diabetes with inadequate glycemic control.
Exenatide extended-release (Bydureon) approved as an add-on therapy to basal insulin in adults with type 2 diabetes with inadequate glycemic control.
Long-term use of dietary supplements may improve C-reactive protein, HDL cholesterol, serum homocysteine, blood pressure, and incidence of diabetes.
A number of complementary and alternative medications can potentially lower blood sugar, and many patients with diabetes look at these substances as more natural than synthetic drugs.
Newly-approved device could reduce the amount of pens adults prescribed to Toujeo need to use.
Top news of the week from The American Journal of Pharmacy Benefits.
In this clip, Traci Fritschle, PharmD, explains why pharmacists are uniquely positioned to be utilized in a team-based model for diabetes care.
WellDyneRx created an innovative program that controls costs and improves outcomes for patients with diabetes, according to a session presented at APhA2018.
Following NDPP guidelines for early prevention programs, The Kroger Co. established patient-centered processed that involved collecting and assessing patient records, while connecting those enrolled in the study with lifestyle coaches.
WellDyneRx has created a comprehensive program to control costs while improving communication and outcomes.
She is director of the Bristol-Myers Squibb Foundation, which works to promote health equity and improve the health outcomes of those disproportionately affected by serious conditions and diseases.
Even with many new developments over the past century, the coordinated use of blood glucose monitors, diabetes medications, and insulin to manage the disease may be too intricate for some patients.
With FDA approval of more than 20 new therapies for diabetes since 2010, clinicians and patients are often overwhelmed with treatment choices.
A team-based approach to diabetes patient care can help improve outcomes, according to a Pharmacy Times® Peer Exchange that addressed this subject recently.
Officials with the FDA have approved Medtronic’s continuous glucose monitoring (CGM) system (Guardian Connect) for use by individuals living with diabetes, according to a company press release.
The Guardian Connect System can alert patients of potential high or low glucose events up to an hour in advance.
ADA urges health care providers to continue to develop personalized care plans that can yield optimal short and long-term results for each individual with diabetes.
Many small health start-ups are leveraging digital health and telemedicine services to provide patient coaching. A new study from one company demonstrates that users could see as much as a 0.8% reduction in A1c.
The American College of Physicians (ACP) recently issued new guidelines aimed at assisting clinicians in making decisions about targets when using pharmacologic therapy in adults with type 2 diabetes.
Clinicians should personalize patient's goals for blood sugar control in type 2 diabetes.
With new smartphones able to measure blood pressure, what does this mean for other companies who solely make these devices?
Proposed federal legislation aims to achieve better health outcomes by giving patients with diabetes the freedom to decide which testing supplies work best for them.
Through clinical and humanistic interventions, pharmacists can improve outcomes and lower costs for patients with diabetes.
Value-based contracts may also improve patient outcomes by increasing access to innovative medicines and supporting appropriate use.